Search
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalInfliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. … Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases [A31469].
Synonyms: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMERProducts: Remsima 120mg solution for injection in pre-filled pen, Remsima 120mg solution for injection in pre-filled syringeInsulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigationalketoacidosis, which is a life-threatening medical emergency. … Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.
Mixtures: Xultophy Pre-filled Pen, Ryzodeg® FlexTouch® 100 U/ml Solution for InjectionCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersInsulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalmedical emergency. … Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalInclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density … lipoprotein cholesterol (LDL-C) levels.
Categories: Compounds used in a research, industrial, or household setting, Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsProducts: Sybrava 284mg/1.5ml Solution for Injection in Pre-filled Syringe, LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalTwo denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides.
Products: Prolia Solution for Injection 60mg Pre-filled Syringe, Prolia Solution for Injection 60mg/ml Pre-filled SyringeErythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalErythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. … It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced.
Synonyms: 1-165-Erythropoietin (human clone λHEPOFL13 protein moiety), glycoform αProducts: Binocrit 2,000 IU/1 ml solution for injection in a pre-filled syringe, Binocrit 10 000 IU/1 ml solution for injection in a pre-filled syringeGolimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationalIn the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. … treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe
Products: Solution for Injection in Pre-filled Syringe 100 mg/1.0 ml, Simponi Solution for Injection in Pre-filled Syringe 50 mg/0.5 mlSatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalSatralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on … Enspryng®, a satralizumab formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors
Synonyms: Humanised anti-IL-6 receptor monoclonal antibodyCategories: Interleukin-6 Receptor AntagonistUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalUstekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. … [A187349] It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling
Products: Stelara Solution for Injection in Pre-Filled Syringe 90 mg/1 mL, Stelara Solution for Injection in Pre-Filled Syringe 45 mg/0.5mLZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigational[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors … Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.
Synonyms: Benzo[d]isoxazol-3-yl-methanesulfonamide, 1,2-Benzisoxazole-3-methanesulfonamideCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates